Maxigen Biotech Inc. (1783.TW)
TWD 46.3
(-0.43%)
TWD 46.3
(-0.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 165.82 Million TWD | 18.95% |
| 2022 | 139.4 Million TWD | 59.02% |
| 2021 | 87.66 Million TWD | 38.47% |
| 2020 | 63.31 Million TWD | 5.32% |
| 2019 | 60.11 Million TWD | 5.36% |
| 2018 | 57.05 Million TWD | 261.4% |
| 2017 | 15.78 Million TWD | 228.91% |
| 2016 | -12.24 Million TWD | 80.55% |
| 2015 | -62.95 Million TWD | -230.65% |
| 2014 | -19.04 Million TWD | -836.88% |
| 2013 | 2.58 Million TWD | -6.51% |
| 2012 | 2.76 Million TWD | 107.66% |
| 2011 | -36.07 Million TWD | -125.46% |
| 2010 | -16 Million TWD | -226.71% |
| 2009 | 12.62 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 28.41 Million TWD | 60.87% |
| 2024 Q2 | 59.73 Million TWD | 110.21% |
| 2023 Q3 | 41.36 Million TWD | -33.65% |
| 2023 Q1 | 44.44 Million TWD | 2.72% |
| 2023 Q2 | 62.34 Million TWD | 40.27% |
| 2023 FY | 165.82 Million TWD | 18.95% |
| 2023 Q4 | 17.66 Million TWD | -57.3% |
| 2022 Q3 | 42.09 Million TWD | 25.72% |
| 2022 Q1 | 20.54 Million TWD | 49.13% |
| 2022 FY | 139.4 Million TWD | 59.02% |
| 2022 Q4 | 43.27 Million TWD | 2.79% |
| 2022 Q2 | 33.48 Million TWD | 62.97% |
| 2021 Q2 | 21.39 Million TWD | -1.06% |
| 2021 Q4 | 13.77 Million TWD | -55.38% |
| 2021 Q1 | 21.62 Million TWD | 6.02% |
| 2021 FY | 87.66 Million TWD | 38.47% |
| 2021 Q3 | 30.87 Million TWD | 44.36% |
| 2020 Q4 | 20.39 Million TWD | 67.16% |
| 2020 Q1 | 10.18 Million TWD | 36.45% |
| 2020 Q2 | 20.53 Million TWD | 101.59% |
| 2020 Q3 | 12.19 Million TWD | -40.59% |
| 2020 FY | 63.31 Million TWD | 5.32% |
| 2019 Q4 | 7.46 Million TWD | -61.7% |
| 2019 Q3 | 19.49 Million TWD | -26.06% |
| 2019 FY | 60.11 Million TWD | 5.36% |
| 2019 Q1 | 6.79 Million TWD | -7.95% |
| 2019 Q2 | 26.36 Million TWD | 288.0% |
| 2018 Q3 | 17.67 Million TWD | -24.96% |
| 2018 Q2 | 23.54 Million TWD | 178.55% |
| 2018 Q4 | 7.38 Million TWD | -58.23% |
| 2018 FY | 57.05 Million TWD | 261.4% |
| 2018 Q1 | 8.45 Million TWD | 142.37% |
| 2017 Q2 | 8.54 Million TWD | 316.36% |
| 2017 FY | 15.78 Million TWD | 228.91% |
| 2017 Q3 | 7.7 Million TWD | -9.83% |
| 2017 Q1 | -3.94 Million TWD | -214.0% |
| 2017 Q4 | 3.48 Million TWD | -54.72% |
| 2016 Q4 | 3.46 Million TWD | 360.26% |
| 2016 Q2 | -3.2 Million TWD | 71.29% |
| 2016 Q1 | -11.17 Million TWD | 60.67% |
| 2016 Q3 | -1.33 Million TWD | 58.51% |
| 2016 FY | -12.24 Million TWD | 80.55% |
| 2015 Q1 | -12.86 Million TWD | 30.36% |
| 2015 Q2 | -15.67 Million TWD | -21.82% |
| 2015 Q3 | -6.01 Million TWD | 61.6% |
| 2015 Q4 | -28.4 Million TWD | -371.98% |
| 2015 FY | -62.95 Million TWD | -230.65% |
| 2014 FY | -19.04 Million TWD | -836.88% |
| 2014 Q2 | -1.85 Million TWD | -175.41% |
| 2014 Q1 | 2.46 Million TWD | 34.57% |
| 2014 Q4 | -18.47 Million TWD | -1474.94% |
| 2014 Q3 | -1.17 Million TWD | 36.87% |
| 2013 Q1 | -1.96 Million TWD | 11.66% |
| 2013 Q3 | 601 Thousand TWD | -71.66% |
| 2013 Q4 | 1.83 Million TWD | 204.66% |
| 2013 FY | 2.58 Million TWD | -6.51% |
| 2013 Q2 | 2.12 Million TWD | 207.72% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q4 | -2.22 Million TWD | -197.6% |
| 2012 Q3 | -749 Thousand TWD | 0.0% |
| 2012 FY | 2.76 Million TWD | 107.66% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | -36.07 Million TWD | -125.46% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -16 Million TWD | -226.71% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 12.62 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 198.4 Million TWD | 16.421% |
| SciVision Biotech Inc. | 177.9 Million TWD | 6.786% |
| Bionime Corporation | 6.2 Million TWD | -2570.768% |
| Pegavision Corporation | 1.65 Billion TWD | 89.986% |
| Visco Vision Inc. | 301.61 Million TWD | 45.02% |